Mineralys Therapeutics raises funds ahead of pending lorundrostat hypertension approval
Mineralys Therapeutics first came to market attention in 2021 when it licensed a novel hypertension candidate, lorundrostat, from Japan’s Tanabe Pharma, agreeing to a modest $1 million upfront payment.
The company’s chief executive, Jon Congleton, disclosed on June 3 2026 that Mineralys has recently secured additional financing to support its operations as it approaches a regulatory decision on lorundrostat.
The funding move is intended to ensure the company can continue development and potential commercialization if the drug receives approval, a step that investors are watching closely.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Mineralys makes money moves before looming hypertension approval”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that